Publication|Podcasts|July 11, 2023

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

In this episode of the Drug Solutions podcast, Felicity Thomas, European/Senior Editor, chats with Sergey Vlasenko, associate vice-president, Pharma/Biopharma, Agilent, about trends impacting bio/pharmaceutical manufacturing. Sergey provides an overview of some of the key trends and then focuses on a novel modality—oligonucleotides—highlighting the specific challenges related to the manufacture of these exciting therapeutics.

About the Speaker

Sergey Vlasenko, associate vice-president, Pharma/Biopharma, Agilent.

Vlasenko joined Agilent in 2018 through its acquisition of the privately owned company ProZyme, a developer and manufacturer of glycan reagents, kits, and standards, required for biotherapeutic protein characterization. Prior to ProZyme, Vlasenko managed the R&D and marketing teams developing and commercializing innovative products for the Pharma and Biopharma industry.

About the Drug Solutions Podcast

Pharmaceutical Technology presents the Drug Solutions podcast, where the editors will chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.